Agios Reports Strong Q1 Product Revenue Growth, Advances Sickle Cell sNDA, Despite Wider Net Loss
AGIO sits 16% above its 52-week low of $22.24.
Summary
Agios Pharmaceuticals reported a wider net loss in Q1 2026 but achieved significant product revenue growth and advanced its pipeline, including plans for an accelerated sNDA submission for sickle cell disease.
Key Events · Earnings and Guidance · AGIO
-
Q1 2026 Financial Results
Reported a net loss of $99.1 million, compared to a net loss of $89.3 million in Q1 2025. Net loss per share was $(1.69).
-
Strong Product Revenue Growth
Worldwide net revenues for mitapivat (PYRUKYND® and AQVESME™) more than doubled to $20.7 million in Q1 2026, up from $8.7 million in Q1 2025.
-
Successful AQVESME Launch
The initial U.S. commercial launch of AQVESME in thalassemia generated 242 prescriptions as of March 31, 2026.
-
Accelerated Approval Pathway for Sickle Cell Disease
Agios plans to submit a supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease under the U.S. accelerated approval pathway in the second quarter of 2026.
Analysis · AGIO · Life Sciences
Agios Pharmaceuticals reported a mixed first quarter, with a wider net loss of $99.1 million and a net loss per share of $(1.69). However, this was significantly offset by strong operational progress. Worldwide net revenues for its mitapivat products more than doubled year-over-year, driven by a successful U.S. launch of AQVESME in thalassemia. The company also announced plans to submit a supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease under the accelerated approval pathway in the second quarter, which could significantly expedite market access for this indication. With $1.0 billion in cash, the company maintains a strong financial position to fund its pipeline and commercialization efforts, indicating a focus on growth and long-term value despite current losses.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AGIO was trading at $25.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $22.24 to $46.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.